RT Book, Section A1 DeMatteo, Ronald P. A2 Zinner, Michael J. A2 Ashley, Stanley W. SR Print(0) ID 57011857 T1 Chapter 25. Perspective on Gastrointestinal Stromal Tumors T2 Maingot's Abdominal Operations, 12e YR 2013 FD 2013 PB The McGraw-Hill Companies PP New York, NY SN 978-0-07-163388-8 LK accesssurgery.mhmedical.com/content.aspx?aid=57011857 RD 2024/03/29 AB In the accompanying chapter, Dr Raut provides an overview of gastrointestinal stromal tumor (GIST). Clearly, the development of tyrosine kinase inhibitors for GIST is one of the most remarkable achievements to date for any solid tumor. Patients with metastatic GIST historically had a median survival of 12 months, but it is now 5 years.1,2 The paradigm of targeted molecular therapy has been subsequently expanded to lung adenocarcinoma with epidermal growth factor receptor (EGFR) inhibitors, renal carcinoma with vascular endothelial growth factor receptor (VEGFR) inhibitors, and most recently melanoma with B-Raf inhibitors. Although GIST is an uncommon tumor, lessons from “the GIST story” will have relevance to the multimodality therapy of these more common tumors and other cancers for which targeted therapy is developed.